Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00338494 · ClinicalTrials.gov registry record · Phase 1

Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma

A Phase 1 study of B-cell Lymphoma, sponsored by Yale University.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target
1
Study location

NCT00338494 is a Phase 1 study of B-cell Lymphoma that has completed, run by Yale University. The registered enrollment target is 16 participants, below the 90-participant average among 38 other B-cell Lymphoma trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00338494, a Phase 1 study of B-cell Lymphoma, has completed, sponsored by Yale University.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

Clofarabine is a new chemotherapy drug which was FDA approved for the treatment of acute lymphocytic leukemia in children. This study is being done to see if Clofarabine works in adult patients with B-cell types of lymphoma. This research is being done to develop new treatments for patients with lymphoma whose cancer has returned or resisted treatment with previous chemotherapy.

Conditions Studied

B-cell Lymphoma

Interventions

  • DRUG Clofarabine

Study Locations (1)

Connecticut

  • Yale Comprehensive Cancer Center at Yale University School of Medicine - New Haven

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2005-10
Est. Completion 2011-04
Phase Phase 1

Sponsor

Yale University

1,492 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00338494

The ClinicalTrials.gov registry entry for NCT00338494 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90-participant average among 38 other B-cell Lymphoma trials with a reported enrollment target (82% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with B-cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Clofarabine is the first listed.

NCT00338494 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT00338494 about?

NCT00338494 is a clinical study titled "Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma". Clofarabine is a new chemotherapy drug which was FDA approved for the treatment of acute lymphocytic leukemia in children. This study is being done to see if Clofarabine works in adult patients with B-cell types of lymphoma. This research is being done to develop new treatments for patients with ly...

What is the current status of trial NCT00338494?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2005-10. Estimated completion is 2011-04.

What conditions does trial NCT00338494 study?

This clinical trial studies the following conditions: B-cell Lymphoma.

What interventions are being tested in trial NCT00338494?

The interventions under investigation include: Clofarabine (DRUG).

Who is sponsoring clinical trial NCT00338494?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00338494 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for B-cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

B-cell Lymphoma

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.